# Phase I Study to Assess the Safety and Immunology of a COVID-19 Vaccine With GRAd-COV2 Vaccine

> **NCT04528641** · PHASE1 · COMPLETED · sponsor: **ReiThera Srl** · enrollment: 98 (actual)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** GRAd-COV2

## Key facts

- **NCT ID:** NCT04528641
- **Lead sponsor:** ReiThera Srl
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-10
- **Primary completion:** 2021-05-19
- **Final completion:** 2021-05-19
- **Target enrollment:** 98 (ACTUAL)
- **Last updated:** 2022-02-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04528641

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04528641, "Phase I Study to Assess the Safety and Immunology of a COVID-19 Vaccine With GRAd-COV2 Vaccine". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT04528641. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*